Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Targeting PI3Kgamma Signaling With Azacitidine, Venetoclax and Eganelisib in Acute Myeloid Leukemia: A Phase 1 Study (GAVEL)

NCT07439211 is registered in ClinicalTrials.gov with Jacqueline Garcia, MD as lead sponsor.

NCT NCT07439211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07439211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Targeting PI3Kgamma Signaling With Azacitidine, Venetoclax and Eganelisib in Acute Myeloid Leukemia: A Phase 1 Study (GAVEL)
Lead sponsor
Jacqueline Garcia, MD
Phase
Phase 1
Overall status
Recruiting
Start date
April 13, 2026
Completion date
February 1, 2029
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, leukemia, leukemia, myeloid, refractory leukemia